- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lupin Ltd (LUPN)
Lupin Ltd stock price live, this page displays NSE LUPN stock exchange data. View the LUPN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lupin Ltd real time stock price chart below.
What Is the Lupin Ltd Stock Price Today?
The Lupin Ltd stock price today is 2,478.50.
What Is the Stock Symbol for Lupin Ltd?
The stock symbol for Lupin Ltd is "LUPN."
What Stock Exchange Does Lupin Ltd Trade On?
Lupin Ltd is listed and trades on the NSE stock exchange.
Is Lupin Ltd a Good Stock to Buy?
Determining whether Lupin Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUPN quote. (ISIN: INE326A01037)
What Is the Lupin Ltd Stock Price Today?
The Lupin Ltd stock price today is 2,478.50.
What Is the Stock Symbol for Lupin Ltd?
The stock symbol for Lupin Ltd is "LUPN."
What Stock Exchange Does Lupin Ltd Trade On?
Lupin Ltd is listed and trades on the NSE stock exchange.
Is Lupin Ltd a Good Stock to Buy?
Determining whether Lupin Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUPN quote. (ISIN: INE326A01037)
2,478.50
+35.30(+1.44%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,424.00
2,494.80
52 wk Range
1,836.80
2,529.50
LUPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,424.002,494.80
52 wk Range
1,836.802,529.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.72%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.72%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
LUPN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- Lupin receives FDA approval for famotidine injection
- Investing.com
- FDA greenlights continued generic access for Micardis
- Investing.com
Pro
- Lupin receives FDA approval for famotidine injection
- Investing.com
- FDA greenlights continued generic access for Micardis
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Earnings
Latest Release
May 06, 2026
EPS / Forecast
34.75 / 26.16
Revenue / Forecast
74.75B / 69.15B
Compare LUPN to Peers and Sector
Metrics to compare | LUPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUPNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 20.9x | 38.4x | −0.4x | |
PEG Ratio | 0.34 | 2.71 | 0.00 | |
Price/Book | 5.0x | 5.5x | 2.6x | |
Price / LTM Sales | 4.0x | 5.0x | 3.0x | |
Upside (Analyst Target) | 4.0% | 5.1% | 53.2% | |
Fair Value Upside | Unlock | −1.7% | 9.0% | Unlock |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Lupin (LUPN) Stock Price Today?
The Lupin stock price today is 2,478.50 INR.
What Stock Exchange Does Lupin Trade On?
Lupin is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Lupin?
The stock symbol for Lupin is "LUPN."
Does Lupin Pay Dividends? What’s The Current Dividend Yield?
The Lupin dividend yield is 0.72%.
What Is the Lupin Market Cap?
As of today, Lupin market cap is 1.13T INR.
What Is Lupin's Earnings Per Share (TTM)?
The Lupin EPS (TTM) is 116.44.
When Is the Next Lupin Earnings Date?
Lupin will release its next earnings report on Aug 11, 2026.
From a Technical Analysis Perspective, Is LUPN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Lupin Stock Split?
Lupin has split 2 times.
How Many Employees Does Lupin Have?
Lupin has 26021 employees.
What is the current trading status of Lupin (LUPN)?
As of Jul 20, 2026, Lupin (LUPN) is trading at a price of 2,478.50 INR, with a previous close of 2,443.20 INR. The stock has fluctuated within a day range of 2,424.00 INR to 2,494.80 INR, while its 52-week range spans from 1,836.80 INR to 2,529.50 INR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.